References of "Schizophrenia Research"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMultitasking capacities in persons diagnosed with schizophrenia: A preliminary examination of their neurocognitive underpinnings and ability to predict real world functioning
Laloyaux, Julien ULg; Van der Linden, Martial ULg; Levaux, Marie-Noëlle ULg et al

in Schizophrenia Research (2014, April), 153(Supl. 1), 344

Background: Difficulties in everyday life activities are core features of persons diagnosed with schizophrenia. Moreover, patients seem to demonstrate particular difficulties during complex and ... [more ▼]

Background: Difficulties in everyday life activities are core features of persons diagnosed with schizophrenia. Moreover, patients seem to demonstrate particular difficulties during complex and multitasking activities, such as cooking a meal (Semkovska et al., 2004). Multitasking refers to activities where the person has to: carry out and alternate between different tasks that vary in terms of priority, difficulty and duration; define the tasks’ targets; and where the person is faced with unexpected problems during the realization of these tasks (Burgess, 2000). However, at present, patients’ multitasking capacities have not been adequately examined in the literature due to an absence of suitable assessment strategies. We thus recently developed a computerized real-life activity task designed to take into account the complex and multitasking nature of certain everyday life activities where participants are required to prepare a room for a meeting – the Computerized Meeting Preparation Task (CMPT) Methods: Twenty-one individuals diagnosed with schizophrenia and 20 matched healthy controls completed the CMPT. During the CMPT, participants found themselves in a virtual room that they had to prepare for a meeting while respecting a list of instructions (the placement of the guests, the needed objects, the desired drinks, etc.). Patients were also evaluated with an extensive cognitive battery (assessing executive functions, attention, processing speed and memory), measures of symptomatology and real world functioning. To examine the ecological validity of the CMPT, 14 others patients were recruited and were given the computerized version and a real version of the meeting preparation task. Results: Results demonstrated that performance on the CMPT significantly differentiated patients and healthy controls for the total time to complete task, planning efficiency, and the respect of the instructions. Moreover, these variables were significantly correlated with executive functioning (i.e. cognitive flexibility and planning), suggesting the major implication of these cognitive processes in multitasking activities. Performance on the CMPT also significantly predicted up to 50% of real world functioning. Finally, performances on the computerized version and the real version of the meeting preparation task were highly correlated, suggesting good ecological validity. Discussion: In this study, we created a novel task involving the multitasking nature of real world activities. The results demonstrated that this approach provides a good indication of the real world functioning in patients diagnosed with schizophrenia. Moreover, results suggest a particular implication of executive functioning in multitasking activities. These findings suggest the importance of evaluating multitasking capacities in patients diagnosed with schizophrenia in order to predict real world functioning. [less ▲]

Detailed reference viewed: 16 (8 ULg)
Full Text
Peer Reviewed
See detailDifferences and similarities in the sensory and cognitive signatures of voice-hearing, intrusions and thoughts
Moritz, S.; Laroi, Frank ULg

in Schizophrenia Research (2008), 102(1-3), 96-107

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailTypical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.
De Hert, Marc; Schreurs, Vincent; Sweers, Kim et al

in Schizophrenia Research (2008), 101(1-3), 295-303

The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at the ... [more ▼]

The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at the onset of the disorder and specifically no data on patients treated in the era when only first-generation antipsychotics were available. METHODS: Data from a historic cohort of consecutively admitted first-episode patients with schizophrenia treated with first-generation antipsychotics (FGAs) were compared with an age and sex matched series of consecutive first-episode patients treated only with second-generation antipsychotics (SGAs). Rates of MetS were compared at baseline and after on average 3 years of treatment exposure. RESULTS: At first episode there was no difference in the prevalence of MetS between the historic and the current cohort. Rates of MetS increased over time in both groups, but patients started on SGAs had a three times higher incidence rate of MetS (Odds Ratio 3.6, CI 1.7-7.5). The average increase in weight and body mass index was twice as high in patients started on SGA. The difference between the FGA and SGA group was no longer significant when patients started on clozapine and olanzapine were excluded. CONCLUSION: Rates of MetS at the first episode of schizophrenia today are not different from those of patients 15 to 20 years ago. This finding counters the notion that the high rates of metabolic abnormalities in patients with schizophrenia currently reported are mainly due to lifestyle changes over time in the general population. Some SGAs have a significantly more negative impact on the incidence of MetS compared to FGAs in first-episode patients. [less ▲]

Detailed reference viewed: 72 (1 ULg)
Full Text
Peer Reviewed
See detailA cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.
Hanssens, Linda; van Winkel, Ruud; Wampers, Martien et al

in Schizophrenia Research (2008), 106(2-3), 308-14

BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The ... [more ▼]

BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The underlying mechanism, however, is poorly understood. Adiponectin is a recently identified adipocyte-derived protein, with low adiponectin levels being associated with metabolic abnormalities such as obesity, insulin resistance and type 2 diabetes. METHODS: Fasting adiponectin levels were assessed in a cross-sectional sample of 386 patients with schizophrenia or schizoaffective disorder. All patients were on monotherapy of second-generation antipsychotics (SGA) and underwent an extensive metabolic screening including an oral glucose tolerance test (OGTT). RESULTS: Adiponectin plasma levels were inversely correlated with BMI, and differed significantly between patients with normal weight, overweight or obesity (p<0.05). Patients who met criteria for the metabolic syndrome, according to adapted National Cholesterol Educational Program - Adult Treatment Panel criteria (NCEP-ATP III) (29.3%), had significantly lower adiponectin levels than patients not meeting metabolic syndrome criteria (p<0.0001). Patients without glucose abnormalities (78%) had significantly higher adiponectin levels than patients with diabetes (5.7%) (p<0.05). After controlling for components of metabolic syndrome and sex, antipsychotic medication independently influenced adiponectin levels (p<0.0001), with the lowest mean levels in patients on clozapine and olanzapine. CONCLUSIONS: Adiponectin levels in schizophrenic patients mirror what is observed in the general population, with the lowest levels in the most metabolically comprised subjects. However, antipsychotic medication may also influence adiponectin regulation independently, a finding that should be confirmed in longitudinal studies. [less ▲]

Detailed reference viewed: 62 (7 ULg)
Full Text
Peer Reviewed
See detailPrevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
De Hert, Marc A.; van Winkel, Ruud; Van Eyck, Dominique et al

in Schizophrenia Research (2006), 83(1), 87-93

The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic syndrome in European patients ... [more ▼]

The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic syndrome in European patients suffering from schizophrenia. Methods: All consecutive patients with schizophrenia at our university psychiatric hospital and affiliate services were entered in an extensive prospective metabolic study including an oral glucose tolerance test. The prevalence of the metabolic syndrome was assessed based on the National Cholesterol Education Program criteria (NCEP, Adult Treatment Protocol, ATP-III), adapted ATP-III criteria using a fasting glucose threshold of 100 mg/dl (AHA) and on the recently proposed criteria from the International Diabetes Federation (IDF). Results: The analysis of 430 patients showed a prevalence of the metabolic syndrome of 28.4% (ATP-III), 32.3% (ATP-III A) and 36% (IDF), respectively. The prevalence of the metabolic syndrome in our sample of patients with schizophrenia is at least twice as high compared to an age-adjusted community sample in Belgium. Conclusion: The metabolic syndrome is highly prevalent among treated patients with schizophrenia. It represents an important risk for cardiovascular and metabolic disorders. Assessment of the presence and monitoring of the associated risks of the metabolic syndrome should be part of the clinical management of patients treated with antipsychotics. (c) 2006 Elsevier B.V. All rights reserved. [less ▲]

Detailed reference viewed: 160 (4 ULg)
Full Text
Peer Reviewed
See detailEffects of aripiprazole on serum lipids, a comparison with patients started on statin
Hanssens, L.; De Hert, M.; Van Eyck, D. et al

in Schizophrenia Research (2006, January), 81(Suppl. S), 135

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailA cross-sectional study of adiponectin in patients with schizophrenia
Hanssens, L.; De Hert, M.; Van Eyck, D. et al

in Schizophrenia Research (2006, January), 81(Suppl. S), 135

Detailed reference viewed: 15 (5 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the metabolic safety of aripiprazole
De Hert, M.; Van Eyck, D.; Hanssens, L. et al

in Schizophrenia Research (2006, January), 81(Suppl. S), 133

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailStatin therapy among schizophrenia patients with dyslipidemia
Wampers, M.; De Hert, M.; Hanssens, L. et al

in Schizophrenia Research (2006, January), 81(Suppl. S), 141

Detailed reference viewed: 28 (4 ULg)
Full Text
Peer Reviewed
See detailUsefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia.
Hanssens, Linda; De Hert, Marc; Van Eyck, Dominique et al

in Schizophrenia Research (2006), 85(1-3), 296-7

Detailed reference viewed: 36 (0 ULg)
Full Text
Peer Reviewed
See detailEmotional processing in a non-clinical psychosis-prone sample
Van't Wout, M.; Aleman, A.; Kessels, R. P. C. et al

in Schizophrenia Research (2004), 68

Symptoms of psychosis have been proposed to form part of a continuous distribution of experiences in the general population rather than being an all-or-nothing phenomenon. Indeed, schizotypal signs have ... [more ▼]

Symptoms of psychosis have been proposed to form part of a continuous distribution of experiences in the general population rather than being an all-or-nothing phenomenon. Indeed, schizotypal signs have been reported in subjects from nonclinical samples. Emotional processing has been documented to be deficient in schizophrenia. In the present study, we tested the hypothesis whether putatively psychosis-prone subjects would show abnormalities in emotion processing. Based on the extremes of Launay-Slade Hallucination Scale (LSHS) ratings of 200 undergraduate students, two groups of subjects (total N= 40) were selected. All 40 participants filled in the Schizotypal Personality Questionnaire (SPQ). We compared both groups on an alexithymia questionnaire and on four behavioral emotional information processing tasks. Hallucination-proneness was associated with an increased subjective emotional arousal and fantasy-proneness. Although no differences between the high and low group were observed on three behavioral emotion processing tasks, on the affective word-priming task presentation of emotional stimuli was associated with longer reactions times to neutral words in high schizotypal subjects. Also, SPQ scores correlated with several emotion processing tasks. We conclude that these findings lend partial support to the hypothesis of continuity between symptoms characteristic of schizophrenia and psychosis-related phenomena in the normal population. (C) 2003 Elsevier B.V All rights reserved. [less ▲]

Detailed reference viewed: 21 (0 ULg)